Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Filgrastim 4Cyclophosphamide 4Psychiatric Rehabilitation 3Palliative Care 3Busulfan 3aflibercept 2Vincristine 2Thalidomide 2Radiotherapy 2Paclitaxel 2Melphalan 2Leucovorin 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2Docetaxel 2Celecoxib 2Azacitidine 2Analgesia 2venetoclax 1trimetrexate glucuronate 1tazemetostat 1tanespimycin 1sargramostim 1romidepsin 1ripretinib 1pembrolizumab 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Glutamic Acid × Other hematologic neoplasm × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡